Neos Therapeutics Inc (NASDAQ:NEOS) – Cantor Fitzgerald issued their FY2018 earnings per share (EPS) estimates for Neos Therapeutics in a note issued to investors on Tuesday. Cantor Fitzgerald analyst L. Chen expects that the company will post earnings of ($1.86) per share for the year. Cantor Fitzgerald has a “Buy” rating and a $20.00 price objective on the stock.
A number of other equities analysts have also weighed in on the company. Zacks Investment Research upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Wells Fargo set a $14.00 price objective on Neos Therapeutics and gave the company a “buy” rating in a research note on Saturday, March 17th. BidaskClub upgraded Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, March 10th. Finally, BMO Capital Markets lowered Neos Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $15.00.
Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Thursday, March 15th. The company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.12. The business had revenue of $7.79 million during the quarter, compared to analyst estimates of $9.30 million. Neos Therapeutics had a negative return on equity of 437.92% and a negative net margin of 264.80%.
Several institutional investors have recently made changes to their positions in NEOS. Cortina Asset Management LLC purchased a new position in shares of Neos Therapeutics in the 3rd quarter valued at about $5,312,000. Lyon Street Capital LLC increased its stake in shares of Neos Therapeutics by 247.5% in the 4th quarter. Lyon Street Capital LLC now owns 783,583 shares of the company’s stock valued at $7,993,000 after purchasing an additional 558,117 shares in the last quarter. BlackRock Inc. increased its stake in shares of Neos Therapeutics by 30.7% in the 4th quarter. BlackRock Inc. now owns 1,861,347 shares of the company’s stock valued at $18,985,000 after purchasing an additional 436,667 shares in the last quarter. Perceptive Advisors LLC purchased a new position in shares of Neos Therapeutics in the 4th quarter valued at about $3,060,000. Finally, Harvest Capital Strategies LLC purchased a new position in shares of Neos Therapeutics in the 4th quarter valued at about $2,237,000. Hedge funds and other institutional investors own 49.33% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3294548/neos-therapeutics-inc-forecasted-to-post-fy2018-earnings-of-1-86-per-share-neos.html.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.